MATSUMOTO Yoko 崇城大学, 生物生命学部, 教授 (00133562)
GOTO Koichi 崇城大学, 生物生命学部, 教授 (30279377)
TANOUE Osamu 崇城大学, 生物生命学部, 助教 (10343716)
ICHIHARA Hideaki 崇城大学, 生物生命学部, 准教授 (70369114)
KURODA Reiko 東京理科大学, 総合研究機構, 教授 (90186552)
|Budget Amount *help
¥79,560,000 (Direct Cost : ¥61,200,000、Indirect Cost : ¥18,360,000)
Fiscal Year 2012 : ¥13,650,000 (Direct Cost : ¥10,500,000、Indirect Cost : ¥3,150,000)
Fiscal Year 2011 : ¥13,650,000 (Direct Cost : ¥10,500,000、Indirect Cost : ¥3,150,000)
Fiscal Year 2010 : ¥15,470,000 (Direct Cost : ¥11,900,000、Indirect Cost : ¥3,570,000)
Fiscal Year 2009 : ¥16,250,000 (Direct Cost : ¥12,500,000、Indirect Cost : ¥3,750,000)
Fiscal Year 2008 : ¥20,540,000 (Direct Cost : ¥15,800,000、Indirect Cost : ¥4,740,000)
“Molecular science of fluctuations toward biological functions” should be important for understanding the origin of life. We have produced hybrid liposomes (HLs) which can be prepared by sonication of vesicular and micellar molecules in a buffer solution. Inhibitory effects of HL without drugs on the growth of various tumor cells were obtained. We have employed HLs for the research of cancers and interesting results are as follows;
(1) A good correlation between the membrane fluidity of HLs and inhibitory effects of HLs for cancer cells was obtained. HLs distinguished between the cancer and normal cells which had higher and lower membrane fluidities respectively, then fused and accumulated preferentially into the membranes of cancer cells.
(2) Significantly chemotherapeutic effects were obtained using mice model of carcinoma after the treatment with HLs without any drug in vivo. There were no abnormal findings on normal rats after administering HLs on the basis of chronic toxicity tests.
(3) In clinical applications, prolonged survival was attained in patients with lymphoma after the intravenous injection of HLs without any side effect after the approval of the bioethics committee.
(4) We have demonstrated that the membranes of thymocyte leukemic cells are more disordered and more fluid than normal cell membranes using molecular dynamics (MD) calculations.
These findings suggest that HLs should be a new type of nanomedicinal anti-cancer agent that targets cancer cell-membranes to trigger apoptotic cell death for various cancer cells.